Heron Therapeutics, Inc. – NASDAQ:HRTX
Heron Therapeutics stock price today
$1.28
-0.27
-17.42%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 10 hours
Heron Therapeutics stock price monthly change
-52.16%
month
Heron Therapeutics stock price quarterly change
-52.16%
quarter
Heron Therapeutics stock price yearly change
-7.19%
year
Heron Therapeutics key metrics
Market Cap | 236.50M |
Enterprise value | 439.34M |
P/E | -1.36 |
EV/Sales | 2.76 |
EV/EBITDA | -1.48 |
Price/Sales | 1.87 |
Price/Book | 21.90 |
PEG ratio | -0.05 |
EPS | -0.61 |
Revenue | 132.09M |
EBITDA | -79.48M |
Income | -80.95M |
Revenue Q/Q | 17.06% |
Revenue Y/Y | 16.04% |
Profit margin | -190.4% |
Oper. margin | -180.83% |
Gross margin | 48.09% |
EBIT margin | -180.83% |
EBITDA margin | -60.17% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeHeron Therapeutics stock price history
Heron Therapeutics stock forecast
Heron Therapeutics financial statements
| Jun 2023 | 31.76M | -42.05M | -132.42% |
|---|---|---|---|
| Sep 2023 | 31.43M | -25.00M | -79.56% |
| Dec 2023 | 34.23M | -10.72M | -31.33% |
| Mar 2024 | 34.67M | -3.16M | -9.11% |
| 2025 | 177.92M | 1.41M | 0.8% |
|---|---|---|---|
| 2026 | 216.53M | 39.5M | 18.24% |
| 2027 | 244.4M | 45.58M | 18.65% |
| 2028 | 288.76M | 62.85M | 21.77% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 201224000 | 240.50M | 119.52% |
|---|---|---|---|
| Sep 2023 | 229199000 | 256.98M | 112.12% |
| Dec 2023 | 222506000 | 256.47M | 115.27% |
| Mar 2024 | 217887000 | 251.65M | 115.5% |
| Jun 2023 | -27.16M | 13.21M | 319K |
|---|---|---|---|
| Sep 2023 | -9.17M | -23.22M | 53.79M |
| Dec 2023 | 2.45M | -8.83M | 199K |
| Mar 2024 | -9.51M | 1.27M | 11K |
Heron Therapeutics alternative data
| Aug 2023 | 203 |
|---|---|
| Sep 2023 | 203 |
| Oct 2023 | 203 |
| Nov 2023 | 203 |
| Dec 2023 | 203 |
| Jan 2024 | 203 |
| Feb 2024 | 203 |
| Mar 2024 | 126 |
| Apr 2024 | 126 |
| May 2024 | 126 |
| Jun 2024 | 126 |
| Jul 2024 | 126 |
Heron Therapeutics other data
100.00%
0.00%
of HRTX is owned by hedge funds
188
-18
118.16M
-289.73K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jul 2023 | 3649635 | 0 |
| Nov 2023 | 310000 | 0 |
| Quarter | Transcript |
|---|---|
| Q1 2024 7 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 12 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 14 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 14 Aug 2023 | Q2 2023 Earnings Call Transcript |
Heron Therapeutics: Zynrelef Potentially Eases Shareholder Pain
Heron Therapeutics Gets Back On Track
Why Heron Therapeutics Is A Compelling Buy Into 2024
Heron Therapeutics: Restructuring Brings About A New Dawn
Cleaning The House May Not Solve Heron Therapeutics' Problems
BioXcel Therapeutics' Igalmi Commercial Launch: Not As Bad As Some May Think
Assessing Pacira BioSciences' Growth Prospects
Heron Therapeutics Is Not Out Of The Woods Yet
Heron Therapeutics: Cash Is A Problem Again
-
What's the price of Heron Therapeutics stock today?
One share of Heron Therapeutics stock can currently be purchased for approximately $1.28.
-
When is Heron Therapeutics's next earnings date?
Unfortunately, Heron Therapeutics's (HRTX) next earnings date is currently unknown.
-
Does Heron Therapeutics pay dividends?
No, Heron Therapeutics does not pay dividends.
-
How much money does Heron Therapeutics make?
Heron Therapeutics has a market capitalization of 236.50M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 17.99% to 127.04M US dollars.
-
What is Heron Therapeutics's stock symbol?
Heron Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "HRTX".
-
What is Heron Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Heron Therapeutics?
Shares of Heron Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Heron Therapeutics's key executives?
Heron Therapeutics's management team includes the following people:
- Dr. Barry D. Quart Chairman & Chief Executive Officer(age: 68, pay: $1,060,000)
- Ms. Kimberly J. Manhard Executive Vice President of Drug Devel. & Director(age: 65, pay: $727,690)
- Mr. John W. Poyhonen Pres & Chief Commercial Officer(age: 65, pay: $720,450)
- Mr. David L. Szekeres Executive Vice President & Chief Operating Officer(age: 51, pay: $647,120)
- Ms. Lisa Peraza Vice President & Chief Accounting Officer(age: 48, pay: $449,060)
-
How many employees does Heron Therapeutics have?
As Jul 2024, Heron Therapeutics employs 126 workers.
-
When Heron Therapeutics went public?
Heron Therapeutics, Inc. is publicly traded company for more then 38 years since IPO on 26 Aug 1987.
-
What is Heron Therapeutics's official website?
The official website for Heron Therapeutics is herontx.com.
-
Where are Heron Therapeutics's headquarters?
Heron Therapeutics is headquartered at 4242 Campus Point Court, San Diego, CA.
-
How can i contact Heron Therapeutics?
Heron Therapeutics's mailing address is 4242 Campus Point Court, San Diego, CA and company can be reached via phone at 858 251 4400.
Heron Therapeutics company profile:
Heron Therapeutics, Inc.
herontx.comExchange:
NASDAQ
Full time employees:
126
Industry:
Biotechnology
Sector:
Healthcare
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
4242 Campus Point Court
San Diego, CA 92121
San Diego, CA 92121
CIK: 0000818033
ISIN: US4277461020
CUSIP: 427746102
